Skip to main content

Table 2 Change from baseline in patient-reported outcome measures with and without MO

From: The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study

  CM With MO CM Without MO
  Fremanezumab   Fremanezumab  
  Quarterly
(n = 201)
Monthly
(n = 198)
Placebo
(n = 188)
Quarterly
(n = 174)
Monthly
(n = 177)
Placebo
(n = 188)
HIT-6
 LSM (SE) −6.0 (0.7) −6.9 (0.6) −4.5 (0.7) −7.0 (0.7) − 6.8 (0.64) −4.5 (0.6)
  LSMD (SE) − 1.5 (0.7) −2.4 (0.7)   −2.4 (0.7) − 2.3 (0.7)  
  P value 0.0356 0.0009   0.0006 0.0012  
MSQoL, RFR
 LSM (SE) 19.6 (1.8) 21.4 (1.8) 14.7 (1.9) 21.9 (2.0) 21.6 (2.0) 14.5 (1.9)
  LSMD (SE) 4.9 (2.0) 6.7 (2.0)   7.4 (2.1) 7.1 (2.1)  
  P value 0.0142 0.0008   0.0005 0.0008  
MSQoL, RFP
 LSM (SE) 17.5 (1.7) 18.4 (1.6) 14.2 (1.7) 16.4 (1.7) 14.2 (1.7) 10.2 (1.7)
  LSMD (SE) 3.2 (1.8) 4.2 (1.8)   6.2 (1.8) 3.9 (1.8)  
  P value 0.0696 0.0200   0.0007 0.0290  
MSQoL, EF
 LSM (SE) 20.2 (2.0) 22.0 (1.9) 17.3 (2.0) 22.4 (2.1) 19.7 (2.1) 16.7 (2.1)
  LSMD (SE) 2.9 (2.2) 4.7 (2.2)   5.7 (2.3) 3.0 (2.3)  
  P value 0.1833 0.0305   0.0118 0.1873  
PHQ-9
 LSM (SE) −2.8 (0.4) −2.3 (0.4) −2.4 (0.4) −2.6 (0.4) −2.3 (0.4) −1.6 (0.4)
  LSMD (SE) −0.5 (0.4) 0.0 (0.4)   −1.0 (0.4) −0.7 (0.4)  
  P value 0.2679 0.9678   0.0155 0.0922  
  1. CM Chronic migraine, EF Emotional function, HIT-6 Six-item Headache Impact Test, LSM Least-squares mean, LSMD Least-squares mean difference, MO Medication overuse, MSQoL Migraine-Specific Quality of Life, RFP Role function–preventive, RFR Role function–restrictive, PHQ-9 Patient Health Questionnaire-9, SE Standard error
  2. LSMD was determined in comparison to placebo